Pfizer Stock Gets Reduced EPS Forecast from Erste Group Bank

Pfizer Inc. (NYSE:PFE) – Research analysts at Erste Group Bank lowered their FY2026 EPS estimates for shares of Pfizer in a report released on Wednesday, October 21st. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings per share of $2.96 for the year, down from their prior forecast of $2.97. The consensus estimate for Pfizer’s current full-year earnings is $2.94 per share.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the business earned $0.78 EPS. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

PFE has been the topic of a number of other research reports. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Cantor Fitzgerald raised their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Scotiabank lifted their price target on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. Five investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.72.

Pfizer Stock Performance

NYSE PFE opened at $29.80 on Monday. The company has a fifty day moving average of $28.30 and a two-hundred day moving average of $26.67. The company has a market capitalization of $169.82 billion, a PE ratio of 9.85, a P/E/G ratio of 2.04 and a beta of 0.32. Pfizer has a 1 year low of $23.62 and a 1 year high of $30.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Institutional Trading of Pfizer

A number of institutional investors have recently modified their holdings of PFE. BlackRock Inc. lifted its holdings in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp increased its holdings in shares of Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Pfizer by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after purchasing an additional 3,999,646 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Pfizer in the 2nd quarter valued at about $1,049,602,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Pfizer by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after purchasing an additional 293,029 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded approval of TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer whose tumors have homologous recombination repair (HRR) gene mutations, including BRCA and non-BRCA mutations. Moving the treatment into an earlier stage of metastatic disease could enlarge the addressable patient population and support future sales growth. Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
• Positive Sentiment: Pfizer also reported Phase 2 results across serotypes for its 25-valent pneumococcal conjugate vaccine candidate, 25vPnC. The update adds visibility to the company’s vaccine pipeline, though the available report does not provide enough detail to assess the results’ commercial significance. Pfizer announces results across serotypes in Phase 2 study of 25vPnC
• Neutral Sentiment: Pfizer’s shares have gained about 29.7% over the past year and are near their 52-week high, prompting discussion over whether the valuation is ahead of the company’s earnings growth. Investors may require further pipeline or operating improvements to justify additional gains. Pfizer Stock Looks Above Fair Value As 30% Run Continues
• Neutral Sentiment: Pfizer was relatively resilient while Moderna and BioNTech declined amid disappointment over cancer-vaccine trial data. The comparison may offer some support for PFE, but it does not directly change Pfizer’s fundamentals. Moderna Tumbles as Cancer Vaccine Selloff Deepens
• Negative Sentiment: Broader healthcare stocks traded lower, creating sector-level pressure on Pfizer. Separately, an experimental Pfizer lung-cancer drug showed a survival benefit in some patients despite a failed trial, leaving its development outlook uncertain rather than providing a clear catalyst. Healthcare Stocks Softer Monday

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.